



Empowering Heterogeneous Networks for Drug-Target Affinity Prediction

Selen Parlar
January 27, 2022


Outline

- Drug Design
- Background
- WideDeepDTA
- Results
- Conclusion


Drug Design

- Discovers candidate chemicals
 - Evaluates against various proteins
- Costly and time-consuming process
-
- Rational design with computers
 - Selecting and improving ligands from a molecule library
- Huge search space
~ 100M chemicals
~ 190M proteins

Drugs & Proteins




Searching High-Affinity Pairs




Data

2D: Molecular
Structure



Fostamatinib
C₂₃H₂₆FN₆O₉P

3D: Molecular
Structure



COc1cc(Nc2ncc(F)c(Nc3ccc4c(n3)N(COP(=O)(O)O)C(=O)C(C)(C)O4)n2)cc(OC)c1OC


1D: SMILES

1D: InChI


1S/C23H26FN6O9P/c1-23(2)21(31)30(11-38-40(32,33)34)20-14(39-23)6-7-17(28-20)27-19-13(24)10-25-22(29-19)26-12-8-15(35-3)18(37-5)16(9-12)36-4/h6-10H,11H2,1-5H3,(H2,32,33,34)(H2,25,26,27,28,29)

Data

2D: Protein
Structure



3D: Protein
Structure




Tyrosine-protein kinase ABL1

1D:Amino Acid
Sequence


```
MLEICLKLVG CKSKKGLSSS SSCYLEEALQ RPVASDFEPQ GLSEAARWNS KENLLAGPSE NDPNLFVALY DFVASGDNTL SITKGEKLRV LGYNHNGEWC EAQTKNGQGW VPSNYITPVN  
SLEKHSWYHG PVSRNAEAYL LSSGINGSFL VRESESSPGQ RSISLRYEGR VYHYRINTAS DGKLYVSSS RFNTLAELVH HHSTVADGLI TTLHPAPKR NKPTVYGVSP NYDKWEMERT  
DITMKHKLGG GQYGEVYEGV WKKYSLTVAV KTLKEDTMEV EEFLKEAAM KEIKHPNLVQ LLGVCTREPP FYIITEFMTY GNLLDYLREC NRQEVNAVVL LYMATQISSA MEYLEKKNFI  
HRDLAARNCL VGENHLVKVA DFGLSRLMTG DTYTAHAGAK FPIKWTAPES LAYNKFSIKS DVWAFGVLLW EIATYGMSPY PGIDLSQVYE LLEKDYRMR PEGCPEKVYE LMRACWQWNP  
SDRPSFAEIH QAFETMFQES SISDEVEKEL GKQGVRGAVS TLLQAPELPT KTRTSRRAAE HRDTTDVPEN PHSKGQGESD PLDHEPAVSP LLPRKERGPP EGGLNEDERL LPKDKKTNLF  
SALIKKKKKK APTPPKRSSS FREMDGQPER RGAGEEEGRD ISNGALFTP LDTADPAKSP KPSNGAGVPN GALRESGGSG FRSPHLWKK S TLTSSRLAT GEEEGGGSSS KRFLRSCSAS  
CVPHGAKDTE WRSVTLPRDL QSTGRQFDSS TFGGHKSEK ALPRKRAGEN RSDQVTRGTV TPPPRLVKKN EEADEVFKD IMESSPGSSP PNLTpkPLRR QVTAPASGL PHKEEAGKGS  
ALGTPAAAP VTPTSAGSG APGTSKGPA EESRVRHKKH SSSEPGRDKG KLSRLKPAPP PPPAASAGKA GKGPSQSPSQ EAAGEAVLGA KTKATSLVDA VNSDAAKPSQ PGEGLKKPVL  
PATPKQSAK PSGTPIAP VPSTLPSASS ALAGDQPSST AFILISTRV SLRKTRQPE RIASGAIKKG VVLDSTEALC LAISRNEQM ASHSAVLEAG KNLYTFCVSY VDSIQQMRNK  
FAFREAINKL ENNLRELQIC PATAGSGPAA TQDFSKLLSS VKEISDIVQR
```

Additional Data






Graphs


- A graph is a non-linear data structure consisting of nodes and edges.
- $G = (V, E, T)$ comprising:
 - A set of nodes V ,
 - A set of edges E , from $u \in V$ to $v \in V$, with relation type τ as $(u, \tau, v) \in E$.





Homogeneous & Heterogeneous Graphs










Embeddings in 2D

Employs text-based representation.

Employs heterogeneous representation.



Öztürk, H., Özgür, A., & Ozkirimli, E. (2018). DeepDTA: deep drug–target binding affinity prediction.

Bioinformatics, 34(17), i821–i829.

Öztürk, H., Ozkirimli, E., & Özgür, A. (2019). WideDTA: prediction of drug–target binding affinity.

arXiv preprint arXiv:1902.04166.

Lee, I., Keum, J., & Nam, H. (2019). DeepConv-DTI: Prediction of drug–target interaction learning with convolution on protein sequences. *PLoS computational biology*, 15(6), e1006811.

Wan, F., Hong, L., Xiao, A., Jiang, T., & Zeng, J. (2019). NeoDTI: neural integration of neighbor

information from a heterogeneous network for discovering new drug–target interactions.

Bioinformatics, 35(1), 104–111.

Luo, Y., Zhao, X., Zhou, J., Yang, J., Zhang, Y., Kuang, W., ... & Zeng, J. (2017). A network
information approach for drug–target interaction prediction and computational drug repositioning
heterogeneous information. *Nature communications*, 8(1), 1–13


M. A., Olayan, R. S., Ashoor, H., Albaradei, S., Bajic, V. B., Gao, X., ... & Essack, M.

(2020). DTiGEMS+: drug–target interaction prediction using graph embedding, graph mining,
and similarity-based techniques. *Journal of Cheminformatics*, 12(1), 1–17..

WideDeepDTA


The first drug-target affinity prediction framework empowers heterogeneous networks with text-based representations.

WideDeepDTA




Metapath2Vec

- A **meta-path** in a heterogeneous graphs, is a path following a specific meta path scheme P.



Metapath2Vec

- Given an heterogeneous network $G = (V, E, T)$ and a meta-path scheme P , the Metapath2Vec model calculates the transition probability. And finds the next node, given the current node, the type of the node and the scheme P .



Dong, Y., Chawla, N. V., & Swami, A. (2017, August). metapath2vec: Scalable representation learning for heterogeneous networks. In *Proceedings of the 23rd ACM SIGKDD international conference on knowledge discovery and data mining* (pp. 135-144).

Graph Creation

1. Chemical Related Information:


- a. SMILES strings
- b. Drug-Side Effect Association
- c. Drug-Disease Association
- d. Text-Based Similarity
- e. ChemBERTa Embeddings
- f. BioBERT Embeddings for diseases and side effects

Graph Creation

1. Chemical Related Information:

- a. SMILES strings
- b. Drug-Side Effect Association
- c. Drug-Disease Association
- d. Text-Based Similarity
- e. ChemBERTa Embeddings
- f. BioBERT Embeddings for diseases and side effects

$$Jaccard(A, B) = \frac{|A \cap B|}{|A \cup B|} \times 100$$



Graph Creation

2. Protein Related Information:


- a. Amino acid sequences
- b. Protein-Disease Association
- c. Text-Based Similarity
- d. ProtBERT Embeddings
- e. BioBERT Embeddings for diseases


Graph Creation


2. Protein Related Information:



- a. Amino acid sequences
- b. Protein-Disease Association
- c. Text-Based Similarity
- d. ProtBERT Embeddings
- e. BioBERT Embeddings for diseases


$$Jaccard(A, B) = \frac{|A \cap B|}{|A \cup B|} \times 100$$













Experiments

- **BDB:** 490 proteins, 924 ligands, ~30K interactions [1]
- 5-fold cross-validation
- Evaluation: R-squared (R^2) and concordance index (CI)


Cold Ligands




Cold Proteins



Warm Biomolecules





Cold Biomolecules



Results

Biomolecule representation through homogeneous graphs:



Model Name	Number of Nodes	Metapaths	Number of Edges
Model (1), (2)	10935	Drug Interacts with Drug	2196820
Model (3), (4)	6963	Drug Similar to Drug	5848540
Model (5), (6)	12675	Protein Interacts with Protein	124536
Model (7), (8)	465	Protein Similar to Protein	1056

∴ Text-based drug-drug similarity can replace drug-drug Interaction.

	Model	Warm		Cold Ligand		Cold Protein		Cold Both	
		CI	R ²	CI	R ²	CI	R ²	CI	R ²
DDI	DeepDTA	0.888 (0.009)	0.781 (0.028)	0.687 (0.096)	0.039 (0.243)	0.759 (0.006)	0.315 (0.049)	0.554 (0.047)	-0.154 (0.164)
	Model1	0.896 (0.009)	0.777 (0.026)	0.664 (0.057)	-0.053 (0.210)	0.779 (0.030)	0.375 (0.104)	0.554 (0.044)	-0.287 (0.184)
	Model2	0.890 (0.014)	0.782 (0.017)	0.640 (0.066)	-0.125 (0.180)	0.768 (0.009)	0.327 (0.072)	0.495 (0.037)	-0.496 (0.211)
DDS	Model3	0.893 (0.005)	0.787 (0.020)	0.651 (0.085)	-0.139 (0.132)	0.775 (0.018)	0.340 (0.082)	0.519 (0.036)	-0.390 (0.235)
	Model4	0.890 (0.006)	0.789 (0.008)	0.666 (0.064)	-0.102 (0.330)	0.774 (0.015)	0.327 (0.075)	0.536 (0.068)	-0.274 (0.269)

∴ Text-based drug-drug similarity can replace drug-drug Interaction.

		Warm		Cold Ligand		Cold Protein		Cold Both	
	Model	CI	R ²	CI	R ²	CI	R ²	CI	R ²
DDI	DeepDTA	0.888 (0.009)	0.781 (0.028)	0.687 (0.096)	0.039 (0.243)	0.759 (0.006)	0.315 (0.049)	0.554 (0.047)	-0.154 (0.164)
	Model1	0.896 (0.009)	0.777 (0.026)	0.664 (0.057)	-0.053 (0.210)	0.779 (0.030)	0.375 (0.104)	0.554 (0.044)	-0.287 (0.184)
	Model2	0.890 (0.014)	0.782 (0.017)	0.640 (0.066)	-0.125 (0.180)	0.768 (0.009)	0.327 (0.072)	0.495 (0.037)	-0.496 (0.211)
DDS	Model3	0.893 (0.005)	0.787 (0.020)	0.651 (0.085)	-0.139 (0.132)	0.775 (0.018)	0.340 (0.082)	0.519 (0.036)	-0.390 (0.235)
	Model4	0.890 (0.006)	0.789 (0.008)	0.666 (0.064)	-0.102 (0.330)	0.774 (0.015)	0.327 (0.075)	0.536 (0.068)	-0.274 (0.269)

∴ Random and PLM initializations are on par with each other.

	Model	Warm		Cold Ligand		Cold Protein		Cold Both	
		CI	R ²	CI	R ²	CI	R ²	CI	R ²
DDI	DeepDTA	0.888 (0.009)	0.781 (0.028)	0.687 (0.096)	0.039 (0.243)	0.759 (0.006)	0.315 (0.049)	0.554 (0.047)	-0.154 (0.164)
	Model1	0.896 (0.009)	0.777 (0.026)	0.664 (0.057)	-0.053 (0.210)	0.779 (0.030)	0.375 (0.104)	0.554 (0.044)	-0.287 (0.184)
	Model2	0.890 (0.014)	0.782 (0.017)	0.640 (0.066)	-0.125 (0.180)	0.768 (0.009)	0.327 (0.072)	0.495 (0.037)	-0.496 (0.211)
DDS	Model3	0.893 (0.005)	0.787 (0.020)	0.651 (0.085)	-0.139 (0.132)	0.775 (0.018)	0.340 (0.082)	0.519 (0.036)	-0.390 (0.235)
	Model4	0.890 (0.006)	0.789 (0.008)	0.666 (0.064)	-0.102 (0.330)	0.774 (0.015)	0.327 (0.075)	0.536 (0.068)	-0.274 (0.269)

∴ Protein-protein similarity creates the richest representations.


		Warm		Cold Ligand		Cold Protein		Cold Both	
	Model	CI	R ²	CI	R ²	CI	R ²	CI	R ²
PPI	DeepDTA	0.888 (0.009)	0.781 (0.028)	0.687 (0.096)	0.039 (0.243)	0.759 (0.006)	0.315 (0.049)	0.554 (0.047)	-0.154 (0.164)
	Model5	0.888 (0.009)	0.773 (0.025)	0.674 (0.095)	-0.031 (0.290)	0.765 (0.017)	0.323 (0.073)	0.551 (0.049)	-0.269 (0.165)
	Model6	0.888 (0.009)	0.777 (0.012)	0.698 (0.083)	-0.020 (0.347)	0.759 (0.019)	0.299 (0.084)	0.561 (0.031)	-0.363 (0.279)
PPS	Model7	0.893 (0.006)	0.775 (0.018)	0.675 (0.083)	-0.067 (0.211)	0.783 (0.010)	0.362 (0.047)	0.557 (0.036)	-0.260 (0.090)
	Model8	0.892 (0.008)	0.785 (0.019)	0.728 (0.046)	0.155 (0.162)	0.773 (0.022)	0.339 (0.086)	0.598 (0.061)	-0.065 (0.297)

∴ Random and PLM initializations are on par with each other.


	Model	Warm		Cold Ligand		Cold Protein		Cold Both	
		CI	R ²	CI	R ²	CI	R ²	CI	R ²
PPI	DeepDTA	0.888 (0.009)	0.781 (0.028)	0.687 (0.096)	0.039 (0.243)	0.759 (0.006)	0.315 (0.049)	0.554 (0.047)	-0.154 (0.164)
	Model5	0.888 (0.009)	0.773 (0.025)	0.674 (0.095)	-0.031 (0.290)	0.765 (0.017)	0.323 (0.073)	0.551 (0.049)	-0.269 (0.165)
	Model6	0.888 (0.009)	0.777 (0.012)	0.698 (0.083)	-0.020 (0.347)	0.759 (0.019)	0.299 (0.084)	0.561 (0.031)	-0.363 (0.279)
PPS	Model7	0.893 (0.006)	0.775 (0.018)	0.675 (0.083)	-0.067 (0.211)	0.783 (0.010)	0.362 (0.047)	0.557 (0.036)	-0.260 (0.090)
	Model8	0.892 (0.008)	0.785 (0.019)	0.728 (0.046)	0.155 (0.162)	0.773 (0.022)	0.339 (0.086)	0.598 (0.061)	-0.065 (0.297)

Heterogeneous representations with disease information

Model (10) - 2D Drug Embeddings by ChemBERTa,
Disease Embeddings by BioBERT



Model (10) - 2D Drug-Disease Embeddings by Metapath2Vec



Model Name	Num. of Drug Nodes	Num. of Protein Nodes	Num. of Disease Nodes	Metapaths	Num. of Edges
Model (9) Model (10)	3387	-	7086	Drug Assoc. with Disease Disease Assoc. with Drug	1991308
Model (11) Model (12)	-	32169	126	Protein Assoc.with Disease Disease Assoc.with Protein	64990
Model (13) Model (14)	3387	32169	7087	Drug Assoc. with Disease Disease Assoc.with Protein Protein Assoc.with Disease Disease Assoc.with Drug	2056298

∴ Disease information improves prediction performance over benchmark.

	Model	Warm		Cold Ligand		Cold Protein		Cold Both	
		CI	R ²	CI	R ²	CI	R ²	CI	R ²
DDiA	DeepDTA	0.888 (0.009)	0.781 (0.028)	0.687 (0.096)	0.039 (0.243)	0.759 (0.006)	0.315 (0.049)	0.554 (0.047)	-0.154 (0.164)
	Model9	0.895 (0.013)	0.786 (0.023)	0.690 (0.050)	-0.025 (0.202)	0.784 (0.010)	0.349 (0.072)	0.567 (0.047)	-0.187 (0.177)
	Model10	0.896 (0.006)	0.784 (0.019)	0.695 (0.056)	0.066 (0.122)	0.779 (0.014)	0.333 (0.089)	0.564 (0.031)	-0.201 (0.095)
PDiA	Model11	0.881 (0.007)	0.759 (0.028)	0.695 (0.036)	-0.010 (0.201)	0.762 (0.017)	0.238 (0.233)	0.543 (0.068)	-0.475 (0.506)
	Model12	0.895 (0.007)	0.794 (0.015)	0.702 (0.046)	0.030 (0.169)	0.785 (0.011)	0.377 (0.078)	0.568 (0.027)	-0.060 (0.146)
DDiPA	Model13	0.878 (0.009)	0.753 (0.020)	0.664 (0.087)	-0.040 (0.097)	0.749 (0.018)	0.268 (0.061)	0.533 (0.063)	-0.300 (0.161)
	Model14	0.882 (0.008)	0.755 (0.022)	0.703 (0.033)	0.030 (0.082)	0.752 (0.013)	0.282 (0.073)	0.578 (0.050)	-0.275 (0.123)

∴ Disease information improves prediction performance over benchmark.

	Model	Warm		Cold Ligand		Cold Protein		Cold Both	
		CI	R ²	CI	R ²	CI	R ²	CI	R ²
DDiA	DeepDTA	0.888 (0.009)	0.781 (0.028)	0.687 (0.096)	0.039 (0.243)	0.759 (0.006)	0.315 (0.049)	0.554 (0.047)	-0.154 (0.164)
	Model9	0.895 (0.013)	0.786 (0.023)	0.690 (0.050)	-0.025 (0.202)	0.784 (0.010)	0.349 (0.072)	0.567 (0.047)	-0.187 (0.177)
	Model10	0.896 (0.006)	0.784 (0.019)	0.695 (0.056)	0.066 (0.122)	0.779 (0.014)	0.333 (0.089)	0.564 (0.031)	-0.201 (0.095)
PDiA	Model11	0.881 (0.007)	0.759 (0.028)	0.695 (0.036)	-0.010 (0.201)	0.762 (0.017)	0.238 (0.233)	0.543 (0.068)	-0.475 (0.506)
	Model12	0.895 (0.007)	0.794 (0.015)	0.702 (0.046)	0.030 (0.169)	0.785 (0.011)	0.377 (0.078)	0.568 (0.027)	-0.060 (0.146)
DDiPA	Model13	0.878 (0.009)	0.753 (0.020)	0.664 (0.087)	-0.040 (0.097)	0.749 (0.018)	0.268 (0.061)	0.533 (0.063)	-0.300 (0.161)
	Model14	0.882 (0.008)	0.755 (0.022)	0.703 (0.033)	0.030 (0.082)	0.752 (0.013)	0.282 (0.073)	0.578 (0.050)	-0.275 (0.123)

∴ PLM initialization improves performance of heterogeneous graphs.

	Model	Warm		Cold Ligand		Cold Protein		Cold Both	
		CI	R ²	CI	R ²	CI	R ²	CI	R ²
DDiA	DeepDTA	0.888 (0.009)	0.781 (0.028)	0.687 (0.096)	0.039 (0.243)	0.759 (0.006)	0.315 (0.049)	0.554 (0.047)	-0.154 (0.164)
	Model9	0.895 (0.013)	0.786 (0.023)	0.690 (0.050)	-0.025 (0.202)	0.784 (0.010)	0.349 (0.072)	0.567 (0.047)	-0.187 (0.177)
	Model10	0.896 (0.006)	0.784 (0.019)	0.695 (0.056)	0.066 (0.122)	0.779 (0.014)	0.333 (0.089)	0.564 (0.031)	-0.201 (0.095)
PDiA	Model11	0.881 (0.007)	0.759 (0.028)	0.695 (0.036)	-0.010 (0.201)	0.762 (0.017)	0.238 (0.233)	0.543 (0.068)	-0.475 (0.506)
	Model12	0.895 (0.007)	0.794 (0.015)	0.702 (0.046)	0.030 (0.169)	0.785 (0.011)	0.377 (0.078)	0.568 (0.027)	-0.060 (0.146)
DDiPA	Model13	0.878 (0.009)	0.753 (0.020)	0.664 (0.087)	-0.040 (0.097)	0.749 (0.018)	0.268 (0.061)	0.533 (0.063)	-0.300 (0.161)
	Model14	0.882 (0.008)	0.755 (0.022)	0.703 (0.033)	0.030 (0.082)	0.752 (0.013)	0.282 (0.073)	0.578 (0.050)	-0.275 (0.123)

∴ Connecting drugs and proteins through diseases lowers performance.


	Model	Warm		Cold Ligand		Cold Protein		Cold Both	
		CI	R ²	CI	R ²	CI	R ²	CI	R ²
DDiA	DeepDTA	0.888 (0.009)	0.781 (0.028)	0.687 (0.096)	0.039 (0.243)	0.759 (0.006)	0.315 (0.049)	0.554 (0.047)	-0.154 (0.164)
	Model9	0.895 (0.013)	0.786 (0.023)	0.690 (0.050)	-0.025 (0.202)	0.784 (0.010)	0.349 (0.072)	0.567 (0.047)	-0.187 (0.177)
	Model10	0.896 (0.006)	0.784 (0.019)	0.695 (0.056)	0.066 (0.122)	0.779 (0.014)	0.333 (0.089)	0.564 (0.031)	-0.201 (0.095)
PDiA	Model11	0.881 (0.007)	0.759 (0.028)	0.695 (0.036)	-0.010 (0.201)	0.762 (0.017)	0.238 (0.233)	0.543 (0.068)	-0.475 (0.506)
	Model12	0.895 (0.007)	0.794 (0.015)	0.702 (0.046)	0.030 (0.169)	0.785 (0.011)	0.377 (0.078)	0.568 (0.027)	-0.060 (0.146)
DDiPA	Model13	0.878 (0.009)	0.753 (0.020)	0.664 (0.087)	-0.040 (0.097)	0.749 (0.018)	0.268 (0.061)	0.533 (0.063)	-0.300 (0.161)
	Model14	0.882 (0.008)	0.755 (0.022)	0.703 (0.033)	0.030 (0.082)	0.752 (0.013)	0.282 (0.073)	0.578 (0.050)	-0.275 (0.123)

∴ Connecting drugs and proteins through diseases lowers performance.

	Model	Warm		Cold Ligand		Cold Protein		Cold Both	
		CI	R ²	CI	R ²	CI	R ²	CI	R ²
DDiA	DeepDTA	0.888 (0.009)	0.781 (0.028)	0.687 (0.096)	0.039 (0.243)	0.759 (0.006)	0.315 (0.049)	0.554 (0.047)	-0.154 (0.164)
	Model9	0.895 (0.013)	0.786 (0.023)	0.690 (0.050)	-0.025 (0.202)	0.784 (0.010)	0.349 (0.072)	0.567 (0.047)	-0.187 (0.177)
	Model10	0.896 (0.006)	0.784 (0.019)	0.695 (0.056)	0.066 (0.122)	0.779 (0.014)	0.333 (0.089)	0.564 (0.031)	-0.201 (0.095)
PDiA	Model11	0.881 (0.007)	0.759 (0.028)	0.695 (0.036)	-0.010 (0.201)	0.762 (0.017)	0.238 (0.233)	0.543 (0.068)	-0.475 (0.506)
	Model12	0.895 (0.007)	0.794 (0.015)	0.702 (0.046)	0.030 (0.169)	0.785 (0.011)	0.377 (0.078)	0.568 (0.027)	-0.060 (0.146)
DDiPA	Model13	0.878 (0.009)	0.753 (0.020)	0.664 (0.087)	-0.040 (0.097)	0.749 (0.018)	0.268 (0.061)	0.533 (0.063)	-0.300 (0.161)
	Model14	0.882 (0.008)	0.755 (0.022)	0.703 (0.033)	0.030 (0.082)	0.752 (0.013)	0.282 (0.073)	0.578 (0.050)	-0.275 (0.123)


Heterogeneous representations with side effect information

Model (18) - 2D Drug Embeddings by ChemBERTa,
Side Effect Embeddings by BioBERT



Model Name	Number of Drug Nodes	Number of Side Effect Nodes	Metapaths	Number of Edges
Model (15), Model (16)	1003	5451	Drug Associates with Side Effect Side Effect Associates with Drug	231742
Model (17) Model (18)	10935	5451	Drug Associates with Side Effect Side Effect Associates with Drug Drug Interacts with Drug	2427902

Model (18) - 2D Drug - Side Effect Embeddings by Metapath2Vec



∴ Side effect information improves prediction performance over benchmark.

	Model	Warm		Cold Ligand		Cold Protein		Cold Both	
		CI	R ²	CI	R ²	CI	R ²	CI	R ²
DSA	DeepDTA	0.888 (0.009)	0.781 (0.028)	0.687 (0.096)	0.039 (0.243)	0.759 (0.006)	0.315 (0.049)	0.554 (0.047)	-0.154 (0.164)
	Model15	0.898 (0.009)	0.791 (0.016)	0.683 (0.040)	-0.074 (0.265)	0.774 (0.015)	0.358 (0.059)	0.561 (0.045)	-0.278 (0.293)
	Model16	0.889 (0.011)	0.776 (0.021)	0.664 (0.068)	-0.196 (0.196)	0.766 (0.022)	0.323 (0.097)	0.580 (0.052)	-0.445 (0.284)
DDI-DSA	Model17	0.892 (0.013)	0.781 (0.021)	0.688 (0.080)	-0.034 (0.245)	0.769 (0.019)	0.352 (0.084)	0.569 (0.041)	-0.303 (0.244)
	Model18	0.899 (0.008)	0.785 (0.017)	0.711 (0.057)	0.217 (0.153)	0.778 (0.014)	0.365 (0.069)	0.607 (0.061)	-0.018 (0.108)

∴ Integrating side effect relation and drug-drug interaction creates the richest representations.

	Model	Warm		Cold Ligand		Cold Protein		Cold Both	
		CI	R ²	CI	R ²	CI	R ²	CI	R ²
DSA	DeepDTA	0.888 (0.009)	0.781 (0.028)	0.687 (0.096)	0.039 (0.243)	0.759 (0.006)	0.315 (0.049)	0.554 (0.047)	-0.154 (0.164)
	Model15	0.898 (0.009)	0.791 (0.016)	0.683 (0.040)	-0.074 (0.265)	0.774 (0.015)	0.358 (0.059)	0.561 (0.045)	-0.278 (0.293)
	Model16	0.889 (0.011)	0.776 (0.021)	0.664 (0.068)	-0.196 (0.196)	0.766 (0.022)	0.323 (0.097)	0.580 (0.052)	-0.445 (0.284)
DDI-DSA	Model17	0.892 (0.013)	0.781 (0.021)	0.688 (0.080)	-0.034 (0.245)	0.769 (0.019)	0.352 (0.084)	0.569 (0.041)	-0.303 (0.244)
	Model18	0.899 (0.008)	0.785 (0.017)	0.711 (0.057)	0.217 (0.153)	0.778 (0.014)	0.365 (0.069)	0.607 (0.061)	-0.018 (0.108)

DDI	Model1	0.896 (0.009)	0.777 (0.026)	0.664 (0.057)	-0.053 (0.210)	0.779 (0.030)	0.375 (0.104)	0.554 (0.044)	-0.287 (0.184)
	Model2	0.890 (0.014)	0.782 (0.017)	0.640 (0.066)	-0.125 (0.180)	0.768 (0.009)	0.327 (0.072)	0.495 (0.037)	-0.496 (0.211)

∴ PLM initialization improves performance of heterogeneous graphs.

	Model	Warm		Cold Ligand		Cold Protein		Cold Both	
		CI	R ²	CI	R ²	CI	R ²	CI	R ²
DSA	DeepDTA	0.888 (0.009)	0.781 (0.028)	0.687 (0.096)	0.039 (0.243)	0.759 (0.006)	0.315 (0.049)	0.554 (0.047)	-0.154 (0.164)
	Model15	0.898 (0.009)	0.791 (0.016)	0.683 (0.040)	-0.074 (0.265)	0.774 (0.015)	0.358 (0.059)	0.561 (0.045)	-0.278 (0.293)
	Model16	0.889 (0.011)	0.776 (0.021)	0.664 (0.068)	-0.196 (0.196)	0.766 (0.022)	0.323 (0.097)	0.580 (0.052)	-0.445 (0.284)
DDI-DSA	Model17	0.892 (0.013)	0.781 (0.021)	0.688 (0.080)	-0.034 (0.245)	0.769 (0.019)	0.352 (0.084)	0.569 (0.041)	-0.303 (0.244)
	Model18	0.899 (0.008)	0.785 (0.017)	0.711 (0.057)	0.217 (0.153)	0.778 (0.014)	0.365 (0.069)	0.607 (0.061)	-0.018 (0.108)

Key Conclusions

- A novel and successful DTA prediction framework is proposed.
- 1D similarity of biomolecules can replace biomolecule interaction information in homogeneous graphs.
- Language model-based vector initialization improves heterogeneous network representations.
- Increasing the heterogeneity of the graph generates richer representations.
- Disease and side effect information yield the largest improvement over the benchmark.

Future Work

- The limited number of protein-protein similarity data limits WideDeepDTA's overall performance.
- Experiments revealed limitations of heterogeneous networks' with pre-trained language models to represent the long protein sequences.
- We encourage further studies to integrate more text-based features into the graphs.

Acknowledgements

Abdullatif Köksal

Asu Büşra Temizer

Cansu Yılmaz

Gökçe Uludoğan

Gönül Aycı

Hakime Öztürk

Hilal Dönmez

Rıza Özçelik

Kutlu Ülgen

Nilgün Kayalı

Nural Özel

Olca Taner Yıldız

Ömer Benzer

Tuna Tuğcu

Tunga Güngör

Veyis Turgut



TUBITAK ARDEB - 119E133 is gratefully acknowledged

Thank you!

